Objective: To compare the bioavailability and pharmacokinetics of famotidine powder and tablets. Methods: Ten healthy volunteers were given a single oral dose of 40mg of famotidine power or tablet. The blood and urine drug levels were determined by reverse-phase HPLC method. Results: The data obtained from the HPLC were analysed automatically by a MCPKP program. The results showed that the curve of famotidine plasma concentration-time data was in line with the one-compartment open model. The relative-bioavailability of famotidine powder was 103%.The tmax,cmax,t1/2k and AUC of famotidine powder and tablets were(1.91±0.44 ), (2.54±0.40)h; (99.4±37.6),(87.0±29.5)ng/ml;(3.21±0.67),(2.49±0.56)h;(627±100),(607±177)h.ng/ml, respectively. Conclusion: The AUC and cmax of 2 formulations are bioequivalent. There is statistical difference in the tmax between 2 formulations.